23 Mar 2022 07:00
SourceBio International plc
("SourceBio", the "Company" or the "Group")
Notice of Results
Investor presentation
SourceBio International plc (AIM: SBI), the international provider of integrated state-of- the-art laboratory services and products, announces that its full year results for the year ended 31 December 2021 will be released on 5 April 2022.
Investor presentation
Jay LeCoque, Executive Chairman, and Tony Ratcliffe, Chief Financial Officer, will provide a live presentation relating to the Company's full year results via the Investor Meet Company platform on Tuesday 5 April at 4.45 pm (BST). The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and add to meet SourceBio International plc, via:
https://www.investormeetcompany.com/sourcebio-international-plc/register-investor
Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.
Contacts:
SourceBio International plc | www.sourcebiointernational.com | |
Jay LeCoque, Executive Chairman | Via Walbrook PR | |
Tony Ratcliffe, Chief Financial Officer |
| |
|
| |
Liberum (Nominated Adviser and Broker) | Tel: 020 3100 2000 | |
Bidhi Bhoma / Richard Lindley / William Hall |
| |
|
| |
Walbrook PR Limited | Tel: 020 7933 8780 or sourcebio@walbrookpr.com | |
Paul McManus / Sam Allen | Mob: 07980 541 893 / 07748 651 727 | |
About SourceBio International plc www.sourcebiointernational.com
SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products with clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four businesses areas:
· Healthcare Diagnostics - histopathology cancer screening and clinical diagnostic services for the NHS and private healthcare providers across the UK and Ireland, including Digital Pathology
· Genomics - DNA sequencing services and Precision Medicine offering for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America
· Stability Storage - shelf-life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA
· Infectious Disease Testing - a range of COVID-19 testing services for commercial enterprises, private healthcare groups and the NHS, including PCR testing under ISO 15189 accreditation. SourceBio also provides employee testing solutions to industry, direct to consumer home test kits and venue testing.
More details on Group operations can be found here: www.sourcebioscience.com.
SourceBio International plc (SBI) is listed on the AIM market of the London Stock Exchange.